Share-based Payment Arrangement, Expense of Oncotelic Therapeutics, Inc. from 31 Dec 2010 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Oncotelic Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 31 Mar 2025.
  • Oncotelic Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $0.
  • Oncotelic Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $0.
  • Oncotelic Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $0, a 100% decline from 2022.
  • Oncotelic Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $900,000, unchanged from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Oncotelic Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $0 $0 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q1 2024 $0 $0 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q1 2023 $600,000 $0 -$300,000 -100% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $900,000 $275,000 01 Oct 2022 31 Dec 2022 10-K 12 Apr 2024 2023 FY
Q3 2022 $300,000 $0 0% 01 Jul 2022 30 Sep 2022 10-Q 18 Nov 2022 2022 Q3
Q2 2022 $25,000 01 Apr 2022 30 Jun 2022 10-Q 22 Aug 2022 2022 Q2
Q1 2022 $300,000 +$300,000 01 Jan 2022 31 Mar 2022 10-Q 22 May 2023 2023 Q1
Q3 2021 $300,000 01 Jul 2021 30 Sep 2021 10-Q 18 Nov 2022 2022 Q3
Q1 2021 $0 -$2,100,000 -100% 01 Jan 2021 31 Mar 2021 10-Q 22 Nov 2021 2021 Q3
Q1 2020 $2,100,000 +$1,759,000 +516% 01 Jan 2020 31 Mar 2020 10-Q 24 May 2021 2021 Q1
Q1 2020 $2,100,000 +$1,759,000 +516% 01 Feb 2020 29 Feb 2020 10-Q 22 Nov 2021 2021 Q3
Q1 2019 $341,000 +$157,000 +85% 01 Apr 2019 30 Apr 2019 10-K 15 Apr 2021 2020 FY
Q1 2019 $212,000 +$28,000 +15% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2019 2019 Q1
Q1 2018 $184,000 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1
Q3 2013 $199,913 01 Jul 2013 30 Sep 2013 10-Q 13 Nov 2013 2013 Q3

Oncotelic Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $0 $0 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
2023 $0 -$900,000 -100% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
2022 $900,000 $0 0% 01 Jan 2022 31 Dec 2022 10-K 12 Apr 2024 2023 FY
2021 $900,000 +$900,000 01 Jan 2021 31 Dec 2021 10-K/A 20 Apr 2023 2022 FY
2020 $0 01 Jan 2020 31 Dec 2020 10-K 15 Apr 2022 2021 FY
2018 $744,000 -$91,000 -11% 01 Jan 2018 31 Dec 2018 10-K 10 Apr 2019 2018 FY
2017 $835,000 +$31,000 +3.9% 01 Jan 2017 31 Dec 2017 10-K 10 Apr 2019 2018 FY
2016 $804,000 -$2,000 -0.25% 01 Jan 2016 31 Dec 2016 10-K 17 Apr 2018 2017 FY
2015 $806,000 +$392,000 +95% 01 Jan 2015 31 Dec 2015 10-K 30 Mar 2017 2016 FY
2014 $414,000 -$265,000 -39% 01 Jan 2014 31 Dec 2014 10-K 25 Mar 2016 2015 FY
2013 $679,000 +$168,000 +33% 01 Jan 2013 31 Dec 2013 10-K 30 Mar 2015 2014 FY
2012 $511,000 -$340,000 -40% 01 Jan 2012 31 Dec 2012 10-K 30 Mar 2015 2014 FY
2011 $851,000 +$1,538,000 01 Jan 2011 31 Dec 2011 10-K 20 Mar 2014 2013 FY
2010 $687,000 01 Jan 2010 31 Dec 2010 10-K 15 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.